<DOC>
	<DOCNO>NCT01384682</DOCNO>
	<brief_summary>MARCH international , multicentre trial planning enroll 380 HIV-1 infected patient currently 2N ( ) RTI + PI/r regimen virologically suppress . Participants randomize ( 1:2:2 ) one three treatment group : continue current treatment regimen , maraviroc dose 150 mg twice daily PI/r , maraviroc 300 mg twice daily 2N ( ) RTI . As participant population HIV RNA &lt; 200 copies/mL , phenotypic assessment tropism use determine tropism , instead employ genotypic assessment tropism sequence V3 loop HIV envelope . The main aim study investigate whether switch maraviroc , combination either RTI PI/r , good keep HIV viral load undetectable combination RTI PI/r . The aim see switch combination maraviroc improve side effect see people take combination therapy include RTI PI/r . The study hypothesis stable , virologically suppress ( plasma HIV-RNA &lt; 200 copies/mL ) patient history prior virological failure , switch either MVC dose 300mg twice daily ( bid ) combine 2N ( ) RTI backbone regimen MVC dose 150mg twice daily ( bid ) current PI/r ( 300mg bid discretion investigator PI/r fosamprenavir/r ) provide similar ( non-inferior ) antiretroviral efficacy compare continuation current 2N ( ) RTI + PI/r regimen .</brief_summary>
	<brief_title>Maraviroc Switch Collaborative Study</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Documented HIV1 infection license diagnostic test time prior study entry Age &gt; 18 year HIV1 RNA &lt; 200 copies/mL plasma least 24 week Stable ( &gt; 24 week ) ART include two N ( ) RTIs PI/r No evidence primary HIV genotypic mutation HIV reverse transcriptase protease patient available resistance test result conduct prior cART and/or viral rebound/failure Provision write , informed consent . CXCR4 CCR5/CXCR4 dual tropic HIV tropism nonreportable tropism result base assessment use proviral DNA Anticipated need modify current cART regimen toxicity management next 6 month The follow laboratory criterion , 1. absolute neutrophil count ( ANC ) &lt; 750 cells/µL 2. haemoglobin &lt; 8.0 g/dL 3. platelet count &lt; 50,000 cells/µL 4. serum AST , ALT &gt; 5 x upper limit normal ( ULN ) Active hepatitis B coinfection Pregnant woman nurse mother Current use prohibit medication describe product specific information . Hypersensitivity soy peanut Acute therapy serious infection serious medical illness ( judgement site Principal Investigator ) require systemic treatment and/or hospitalisation Use immunomodulators ( e.g . systemic corticosteroid , recombinant interleukin2 , interferon ) within 30 day prior screen Patients current alcohol illicit substance use opinion site Principal Investigator would conflict aspect conduct study Patients unlikely able remain followup protocoldefined period Prisoners subject compulsorily detain ( involuntary incarcerate ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>